News
Novavax said Monday that the Food and Drug Administration was asking the company to run a new clinical trial of its vaccine.
6don MSN
The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...
Dr. Marty Makary, chief of the FDA, has expressed doubts about the agency approving the COVID-19 vaccine for winter, stating ...
“Under Secretary Kennedy’s leadership, all new vaccines will undergo safety testing in placebo-controlled trials prior to ...
The FDA is expected to unpause the only protein-based COVID-19 vaccine's transition from emergency approval to full approval.
Confusion over the FDA delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend, with possible ...
Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...
Novavax Inc. shares fell after the Wall Street Journal reported that US regulators asked the company to conduct another ...
A new randomized study could cost Novavax tens of millions of dollars, vaccine experts say ...
The head of the Food and Drug Administration said Tuesday that the agency is now looking at whether it will still approve COVID-19 vaccines for next winter, citing a lack of data on booster shots.
Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full ...
Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results